

## **Conference Overview**

Welcome to the 2021 CAPT-ACTP conference! The theme of the conference, “*Evidence in a time of Crisis*” could not be more fitting for this year. As we entered the second year of hosting a virtual conference in the midst of a pandemic- no lesson has been greater than the urgency and importance for strong scientific evidence. There have been important leaps made and lessons learned that will remain with the scientific community even after the pandemic is just a chapter in history books. This important chapter in history has brought forward new challenges to the scientific community on how to develop robust evidence quickly, deal with uncertainty and communicate science to the public.

While our conference looks a bit different this year, the Scientific Program Committee has been working hard with our partners to ensure that we are still able to deliver content that is valuable to our audience. Through our diverse program this year, we have continued focused on selecting timely topics that align with CAPT-ACTP’s Vision of linking population-based therapeutic research, policy and practice to lead to improved health outcomes. More importantly we aim to share ideas and spark discussions that we hope will move research in our space forward. We are pleased to present a number of panel discussions, which bring together the diverse perspectives and expertise of our speakers and membership. This year, we are proud to be able to once again showcase the exciting research achievements

The Scientific Program Committee would like to thank our partners who have made the presentation of this year’s conference possible, and have continued to support CAPT-ACTP despite continued challenges this year. We hope that it won’t be long before we are able to safely enjoy the company of each other in person at the conference, and we look forward to those days in anticipation. Until then, we look forward to meeting you virtually. We hope that you enjoy the conference!

**Mina Tadrous**  
**CAPT-ACTP Scientific Program Committee Chair**

**Monday, October 25, 2021**

**11:00AM – 11:15AM**

**Welcome to Day 1**

Speaker: Shazia Hassan, CAPT-ACTP President

**11:15AM – 12:00PM**

**The Impact of COVID on Cancer Care**

**Sponsored by: Merck**  **MERCK**  
*Be well*

Moderator: Mina Tadrous, Women's College Hospital  
Speakers: Dr. Gerald Batist  
MJ DeCoteau, Executive Director of Rethink Breast Cancer

**Session Overview:** The COVID-19 pandemic has taken a devastating toll on Canadians and our society. However, as our collective attention remains on fighting the virus, another pressing pandemic is surging – rapidly rising cancer rates. Due to more limited screening, later diagnoses and delayed surgeries because of the pandemic, oncologists are now warning of a “tsunami of cancer” in Canada. Canadian health systems need to adapt quickly to catch up to the current care and treatment backlog, while preparing our country for more cancer as our population grows older.

Join us for an in-depth discussion on how Canadian health systems can leverage COVID-19 learnings and new health innovations and solutions to revitalize our health system and prepare it for the cancer challenges of the future

**12:00PM – 1:30PM**

**Session 1:** Closing the gaps to timely patient access

**Sponsored by: AstraZeneca** 

Moderator: Dr. Judith Glennie – J.L. Glennie Consulting  
Speakers: HTA/regulatory expert - TBA  
Giles Gershon – Deputy Minister Economic Development + Red Tape Reduction Secretariat, Government of Ontario  
Dr. Paul Wheatly-Price – medical oncologist; Lung Cancer Canada  
Eva Villalba - Executive Director – Quebec Cancer Coalition

**Session Overview:** There have been several efforts in Canada to shorten the time between Health Canada (HC) approval and the patient actually having access to the medication. Health Canada's Project Orbis and collaboration between HC, CADTH, and INESSS on parallel reviews have contributed to accelerated regulatory and HTA reviews for products where early clinical data is promising and there is high patient need. Unfortunately, these advances are being undermined by the reimbursement process. Gains being made to accelerate the first part of the overall access process

through progressive policy advancements like Project Orbis, are rendered ineffectual when product reimbursement takes an additional 12 to 18 months to achieve.

There is a need for better pull through of products that have gone through these accelerated regulatory and HTA processes, so that patients do not end up waiting for medication due to barriers in other parts of the patient access system. It is critical to optimize reimbursement process timelines for important new medications by resolving issues that create barriers with the current system. COVID has shown us that the Canadian health system can pivot and adapt during times of crisis. The *status quo* in patient access to medications should be considered a crisis and addressed accordingly. There must be a willingness to bring creativity and change (i.e., conditional funding mechanisms) to what has become a stagnant process.

The panel will review and discuss options for accelerating access to medicines with high unmet need based on various proposals for a conditional funding mechanism. Diverse perspectives and critiques on the options tabled will serve as the focus of the session.

**1:30PM – 1:40PM      Break**

**1:40PM – 3:10PM      Session 2:      CAR-T- RWE generations and impact on HTA  
(International experience)**

**Sponsored by: Gilead**  **GILEAD**  
Advancing Therapeutics.  
Improving Lives.

Moderator:

Speakers: Dr. Christian Chabannon - (EBMT registry)  
Dr. Marcelo Pasquini - (CIBMTR registry)  
Imi Faghmous - (Kite methodologist)

**Session Overview:** this session will identify and describe the challenges associated with evidence generation and value assessment for highly innovative novel therapies using the example of CAR T. Showcase international examples of RWE collection and utilization for CAR T

3:15PM - 4:00PM

**Oral Presentation Part 1**

*Sponsored by: Amgen, J.L. Glennie Consulting, PDCI*



**Breakout Room 1: Show me the \$\$\$**

Moderator:

Medication use and healthcare costs among adults with migraine: a population-based study in Alberta, Canada

*Presenter: Karen Martins*

Uncovering the hidden costs of Take Home Cancer Drugs (THCDs)

*Presenter: Dylan Lamb-Palmer*

Depression-related healthcare costs associated with treatment patterns among patients with mild-to-severe psoriasis: A retrospective cohort study in Quebec, Canada

*Presenter: Raymond Milan*

**Breakout Room 2: Drug Utilization**

Moderator:

Patterns of antipsychotic dispensation to residents of long-term care facilities in Nova Scotia, Canada including after a fall-related hospitalization

*Presenter: Shanna Trenaman*

Chronic and high dose opioid prescribing patterns for non-cancer patients in primary care practices in Nova Scotia, Canada from 2011-2018

*Presenter: Heather Neville*

Effect of two different types of exercise volumes on exercise capacity, physical activity and quality of life in subjects undergoing percutaneous coronary intervention

*Presenter: Adriana Angarita-Fonseca*

4:00PM – 4:15PM

**Day 1 Summary**

Speaker: Shazia Hassan, CAPT-ACTP President

**Presentation of the Kris Schindel Award**

Remarks from recipient

**Tuesday, October 26, 2021**

**11:00AM – 11:15AM**

**Welcome to Day 2**

Speaker: Shazia Hassan, CAPT-ACTP President

**11:15AM – 12:00PM**

**Keynote Address**

**Sponsored by: CAPT-ACTP**



Moderator: Mina Tadrous, Women's College Hospital

Speaker: Dr. Lorne Tyrrell



Title: Vaccine selection: decision making in real-time during a pandemic

D. Lorne Tyrrell OC, AOE, MD, PhD, FRCPC, FRSC, FCAHS is a Distinguished University Professor at the University of Alberta. He is the Founding Director of the Li Ka Shing Institute of Virology and has focused his research since 1986 on viral hepatitis. His work on the development of antiviral therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 200 countries worldwide for the treatment of HBV. He has also been involved in the establishment of a biotech company—KMT Hepatech Inc. based on the first non-primate animal model for HCV. This model supports the replication of HAV, HBV, HCV and malaria.

Dr. Tyrrell was the Dean of the Faculty of Medicine and Dentistry from 1994-2004. Since leaving the Deanship in 2004, Dr. Tyrrell has taken on a number of important board positions in healthcare in Alberta and Canada. These include the Chair of the Board of the Institute of Health Economics (2004-2018), Chair of the Gairdner Foundation Board (2009-2019), and member of the Research Advisory Council for the Canadian Institute for Advanced Research (2004-2019). He was appointed to the Science Advisory Board to Health Canada and was Chair of the Board of the Health Quality Council (2004-2012).

Since the COVID-19 pandemic, he has worked on antivirals and vaccines for SARS-CoV-2. He is a member of the COVID-19 Vaccine Task Force that advises the Federal Government on the selection of COVID-19 vaccines based on efficacy, safety, and timely availability for Canada.

For his studies on viral hepatitis, Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), Officer of the Order of Canada (2002), Alberta Order of Excellence (2000) and Fellow of the Royal Society (2004). He was inducted into the Canadian Medical Hall of Fame in April 2011 and was awarded the Killam Prize Health Sciences in May 2015

**12:00PM – 1:30PM Session 3: Developing a framework for Using RWE in HTA & payer decisions for highly innovative technologies for rare diseases (RDs) – a working session**

**Sponsored by: IQVIA** 

Moderator:

Speakers: HTA Expert, Public Payer, Patient Group, Clinician, Manufacturer, Analytics Expert

**Session Overview:** (Case Study) Challenging a group of diverse stakeholders to examine in real-time how RWE can be used to address uncertainty and improve access in a proactive approach.

**1:30PM – 01:45PM Break (Sponsored by: )**

**1:45PM – 3:15PM Session 4: Patient Support Programs (PSP) and Rare Disease: Utilization of RWE in Strategy**

**Sponsored by: Innomar Strategies**   
AmerisourceBergen  
Innomar Strategies

Moderator: Alison Drinkwater – Senior Director, Strategic Consulting, Innomar Strategies

Speakers: Sandra Salama-Anderson - Senior Vice President, Commercialization and Strategy, Innomar Strategies  
Nedzad Pojskic – Vice- President, Pharmacy Benefits Management, Greensheild Canada  
Durhane Wong-Reiger- President &CEO, Canadian Organization for Rare Diseases (CORD)  
TBD

**Session Overview:** The session will explore how to leverage patient support programs (PSP) throughout the product life cycle and identify the challenges and opportunities associated with utilizing the PSP for RWE to enable decision-making and market access/commercialization strategies of rare disease therapies. This will be presented from the unique perspectives of the panelists embodying the patient voice, manufacturer, private payer and leader in PSPs, who will share key initiatives in Canada to address challenges in rare diseases.

**3:15PM – 3:30PM Break**

**3:30PM – 4:15PM Oral Presentations Part 2**

**Sponsored by: Amgen, J.L. Glennie Consulting, PDCI**



**Breakout Room 1: Topics in COVID-19**

Moderator:

Exploring associations between polypharmacy and COVID-19-related hospitalizations and deaths: a population-based study among community-dwelling older adults in Quebec

*Presenter: Caroline Sirois*

Prescribing patterns among in-person vs virtual primary care visits pre- and post-COVID-19 in Ontario, Canada

*Presenter: Sergey Muratov*

Utilization of COVID-19 related funding modifications for systemic cancer therapies in Ontario, Canada

*Presenter: Jaclyn Beca*

**Breakout Room 2: Pharmacoepidemiology**

Moderator:

Hydrochlorothiazide use and risk of non-melanoma skin cancer (NMSC)

*Presenter: Cristiano Moura*

Marginal structural models with latent class growth modeling of time-varying treatment

*Presenters: Awa Diop & Caroline Sirois*

The risk of urinary tract infections associated with the use of sodium-glucose cotransporter-2 inhibitors: A cohort study using real world data.

*Presenter: Wajd Alkabbani*

**4:15PM – 4:30PM Day 2 Summary – awards presentations**

Speaker: Shazia Hassan, CAPT-ACTP President 2021

11:00AM – 11:15AM

**Welcome to Day 3**

Speaker: Shazia Hassan, CAPT-ACTP President

11:15AM – 12:45PM **Session 5:** New Methods in Lifecycle HTA to Manage Uncertainty

**Sponsored by: IHE**  **INSTITUTE OF HEALTH ECONOMICS**  
ALBERTA CANADA

Moderator: Dr. Chris McCabe - Executive Director and CEO, Institute of Health Economics

Speakers: Dr. Diane Kleinermans - President of the Commission of Drugs Reimbursement, National Institute for Health and Disability Insurance (Brussels)  
Dr. Jeff Round – Director, Health Economics, Institute of Health Economics  
Professor Carole Longson - Senior Adviser and Consultant in Life Science Policy, HTA and Market Access

**Session Overview:** This session will identify the challenges associated with decision-making and contracting for reimbursement of therapeutics with high cost, high uncertainty. It will share key initiatives in Canada and at IHE to address the identified challenges, and describe methods for lifecycle HTA that support the use of RWE-informed approaches to reimbursement.

12:45PM – 1:00PM **Break**

1:00PM – 2:30PM **Session 6:** Whose perspective, modeling in a time of crisis– What has the pandemic taught us?

**Sponsored by: Biogen** 

Moderator:

Speakers: CADTH, NICE UK, Provincial Payer, Caregiver, Public member

**Session Overview:** This session will identify the challenges associated with quantifying the impact of the pandemic (healthcare vs societal perspective) from a Health Economic perspective. Share key learnings of societal impact of the pandemic vs taking a narrow perspective of the payer. What would we have missed and how do we credibly quantify this? Lessons learnt for disease areas that have high social impact e.g. Alzheimers/ Hepatitis C? Lessons learnt from other HTA bodies on the implications of the societal vs MOH perspective e.g. NICE, UK

2:30PM – 3:00PM

**Closing Remarks**

Speaker: Mina Tadrous, CAPT-ACTP incoming President



**Abstract Booklet and Posters** can be found at <https://www.capt-actp.ca/conference/>

For any inquiries, please contact Ms. Peggy Kee ([peggy.kee@sunnybrook.ca](mailto:peggy.kee@sunnybrook.ca)), or visit the CAPT-ACTP website at: ([www.capt-actp.ca](http://www.capt-actp.ca)).

### **2021 Conference Partners**

#### **LEVEL 1**

AstraZeneca Canada Inc.  
Biogen  
Gilead Sciences Canada Inc.  
IHE Institute of Health Economics  
Innomar Strategies Inc.  
IQVIA

#### **LEVEL 3**

Merck Canada

#### **LEVEL 3**

Amgen Canada Inc  
J.L. Glennie Consulting Inc.  
PDCI

#### **LEVEL 4**

Astellas  
HOPE Research Centre  
Leo Pharma



We gratefully acknowledge sponsorship of the 2020 CAPT-ACTP conference by the following donors:

LEVEL 1 PARTNERS

**AmerisourceBergen**  
Innomar Strategies

**AstraZeneca**

**Biogen.**

 **GILEAD**  
Advancing Therapeutics.  
Improving Lives.

**IHE** INSTITUTE OF  
HEALTH ECONOMICS  
ALBERTA CANADA

**IQVIA™**

LEVEL 2 PARTNERS

 **MERCK**  
*Be well*

LEVEL 3 PARTNERS

**AMGEN**

**PDCI** | MARKET  
ACCESS

J.L. Glennie Consulting Inc.



LEVEL 4 PARTNERS



DRAFT